canertinib has been researched along with cl 387785 in 3 studies
Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (cl 387785) | Trials (cl 387785) | Recent Studies (post-2010) (cl 387785) |
---|---|---|---|---|---|
124 | 9 | 65 | 34 | 0 | 14 |
Protein | Taxonomy | canertinib (IC50) | cl 387785 (IC50) |
---|---|---|---|
Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.001 | |
Epidermal growth factor receptor | Homo sapiens (human) | 0.0456 | |
Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.1952 | |
Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.012 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barf, T; Kaptein, A | 1 |
Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
1 review(s) available for canertinib and cl 387785
Article | Year |
---|---|
Irreversible protein kinase inhibitors: balancing the benefits and risks.
Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors | 2012 |
2 other study(ies) available for canertinib and cl 387785
Article | Year |
---|---|
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |